Oxford Science Enterprises
Oxford Science Enterprises (OSE) is the investment arm of Oxford University, focused on commercializing breakthrough research from one of the world's leading research universities. They invest in deep tech, life sciences, and healthtech companies with origins in Oxford's research ecosystem.
Location
Oxford, United Kingdom
Founded
2015
AUM
£900M+
Investment Range
£1M - £50M
Portfolio Companies
1
Focus
biotech-focused
Fund Stages
seed, series-a, series-b, series-c
Investment Thesis
Oxford Science Enterprises backs companies built on transformative science from Oxford University and beyond. They focus on deep tech and life sciences companies with differentiated intellectual property and potential for significant impact, providing patient capital and access to Oxford's research ecosystem.
Team
Partners / Managing Directors (Health & Bio Focus)
- Chris Sherwell - Partner
- Paul Lee - Partner
- Heather Roxborough - Partner
Other Key Team Members
- Deep connections to Oxford University research community
Focus Areas
- Life sciences and therapeutics
- Deep tech
- Healthtech
- Diagnostics
- Genomics
- AI/ML in healthcare
- University spinouts
Notable Exits
- Base Genomics - Acquired by Exact Sciences (2020, cancer epigenetics)
- Vaccitech - IPO (2021, vaccine technology, Oxford/AstraZeneca COVID vaccine)
- Multiple Oxford spinout successes
Notable Investments
- Companies emerging from Oxford University research
- Focus on breakthrough science commercialization
Sources
- https://oxfordscienceenterprises.com
- https://oxfordscienceenterprises.com/team
- Oxford University news
- PitchBook
Portfolio Companies
| Name | Location | Founded | Categories |
|---|---|---|---|
| Base Genomics | Oxford, United Kingdom | 2015 | genomicsdiagnostics+3 |